Meet our Management Team
Antibe’s senior team is based in Toronto, Canada. We are supported by a global network of advisors and subject matter experts covering scientific, clinical and regulatory affairs, investor relations and business development.
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures. |
JD Queen’s University, Canada Law Society of Upper Canada New York State Bar, USA Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.
|
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
John is widely recognized as an expert in gastrointestinal inflammation and in the development of innovative anti-inflammatory medicines. In the mid-1990s, he co-founded NicOx and chaired its Scientific Advisory Board. (NicOx was the first company to achieve regulatory approval for drugs using gasotransmitters.) | PhD Medical Science University of Toronto, Canada British Pharmacological Society Royal Society of Canada
John received the Premier’s Summit Award in Innovation in 2009, financially the largest prize awarded to an individual scientist in Canada. He is also the recipient of the 2011 William Harvey Medal from the William Harvey Institute in London, UK. John was awarded the Heymans Foundation Medal in 2013—one of only twelve scientists so honored since the foundation was established nearly 50 years ago. |
“Gastrointestinal damage from NSAIDs has been a clinically significant problem since first observed with aspirin, which was introduced more than 100 years ago.”
As a scientist and drug development executive, David has extensive experience in bringing drugs from early investigation to regulatory approval. Acting as a product development consultant for several major pharmaceutical firms, he has advanced treatments for bacterial infections and disorders of the central nervous and gastrointestinal systems. | PhD Clinical Pathology and Biochemistry University of Toronto, Canada |
“I value the opportunity to develop a platform that validates a novel NSAID—a drug that can improve the quality of life for so many people suffering from daily pain.”
Alain is a seasoned CFO and consultant to private and public companies. He is a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies in challenging circumstances, such as extreme growth or a fundamental change in business model. | MBA International Institute for Management Development (IMD), Switzerland BComm (Honours) Queen’s University, Canada |
“I see Antibe’s mission in the context of my own family—my grandfather had major stomach surgery because of NSAIDs.”
With more than 25 years of experience in the design and management of new drug development programs, Craig is an expert in gaining regulatory approval in key markets worldwide. His work has involved corporate representation at regulatory agencies, including the FDA, Health Canada, MHRA (UK), and the EMA (EU). | PhD Microbiology University of Glasgow, UK Postdoctoral studies as Fulbright Scholar at Harvard University, USA |
“In a landscape dominated by specialized drugs for rare diseases, I’m excited to work on a pipeline that targets safer analgesia for billions of people.”
With more than 20 years of capital markets experience in life sciences, Christina’s background includes positions in investment banking, equity sales and investor relations. | BBA Wilfred Laurier University, Canada |
“At Antibe, what drives me is the dramatic difference our drugs could make to the lives of millions of patients.”
Scott brings a unique perspective to funding and growing healthcare companies from his broad capital markets experience, where he was able to leverage his academic background in life sciences and computer engineering. His interest in biotechnology was sparked by the Human Genome Project and his studies in biomedical computing. | MEng Computer Engineering University of Toronto, Canada |
“What struck me about Antibe from the beginning was that they were targeting a massive medical problem that has been largely unsolved for decades.”
| A business development executive and scientist, Ella was most recently Vice President, Business Development for Advanced Proteome Therapeutics, a publicly traded biopharma company. Earlier, she was Global Brand Manager for Nordion, where she was responsible for product marketing in the US and Asia. As Director of Business Development for IMV (NASDAQ: IMV), she spearheaded its critical licensing deal with Merck. |
MSc Medical Genetics University of Toronto, Canada
MBA Dalhousie University, Canada Ella is founding CEO and director of TO Health!, a unique platform to convene the Toronto Region Health Cluster and develop the biotech sector — launched by the Toronto Region Board of Trade and incubated by MaRS Discovery District. |
“When it comes to building strong partnerships, there’s no substitute for relationships, reputation and good data!”
As a communicator and strategist, Philip has been contributing to the Antibe project since 2006. Over his career, he has been a senior advisor in pharma, dental products, medical devices, fintech, and a range of internet and IT technologies. He is co-founder of Simon/Ross + Associates, which became the world’s leading Apple-focused computer training company, and a former lecturer in the Department of Computer Science at the University of Toronto. | MBA Harvard Business School, USA BCom McGill University, Canada Philip was co-founder and marketing head of Workfire Networks, a breakthrough internet infrastructure company acquired for $100 million by Packeteer. |
“The year I began working with Antibe, my mom had emergency surgery because of NSAIDs … so this is personal!”